The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...

Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no ...

Try it free for 7 days Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese ...

NPM-139 is a small, subdermal semaglutide implant. Semaglutide is the active ingredient in popular weight-loss drugs such as Ozempic or Wegovy. Vivani Medical CEO Adam Mendelsohn said products ...

ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

subdermal GLP-1 implant and reaffirming previous estimates that top-line results should be available in mid-2025. “We are excited to report that the first dose of the NPM-115 implant was successful.

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...